Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM
Shots:
- The P-I/II dose-finding study evaluates rilzabrutinib in 60 patients with heavily pre-treated ITP
- The results showed that 24 of 60 patients achieved 1EPs & 18 out of 45 patients who initiated rilzabrutinib (400, BID mg) also met its 1EPs. The therapy also showed a rapid & durable increase in platelet count with an acceptable safety profile & the median time to 1st platelet count of 50×109/L was rapid at 11.5 days, was maintained in patients with primary platelet response for a mean of 65% @24wks., 52% experienced 1 TRAEs with no grade ≥3 TRAEs or SAEs
- The therapy is also being evaluated in an ongoing P-III (LUNA 3) study in adults & adolescents aged ≥12yrs. with persistent/chronic ITP
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
